A Study of Inhaled AZD8630 in Adolescents With Asthma

Launched by ASTRAZENECA · Jul 3, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new asthma treatment called AZD8630, which is given as a single inhaled dose using a dry powder inhaler. The main goal is to see how the medicine behaves in the body, how safe it is, and how well the inhaler works in teenagers with asthma. This is an early-phase study, meaning researchers are primarily checking safety and how the drug is processed by the body.

The trial is looking for adolescents who have asthma and regularly use daily asthma medication prescribed by their doctor. To join, participants need to have a certain level of lung function (measured by a simple breathing test) and relatively well-controlled asthma. Teens with other serious health issues, recent severe asthma attacks, or recent respiratory infections may not be eligible. If chosen, participants will receive a single dose of the inhaled medicine and will be monitored closely for safety and how their body responds. This study is currently recruiting, offering an opportunity for eligible teens to help researchers learn more about this potential new asthma treatment.

Gender

ALL

Eligibility criteria

• Key Inclusion Criteria:
• • Physician prescribed daily use of asthma medication.
• • Pre-bronchodilator Forced expiratory volume in one second (FEV1) ≥ 50% of the predicted normal value.
• • Asthma control questionnaire-5 (ACQ-5) \< 1.5 at Screening and Study Day 1.
• Key Exclusion Criteria:
• • History of any clinically important disease or disorder.
• • History of any chronic respiratory disorders (except asthma).
• • Acute exacerbation of asthma within 4 weeks of Screening.
• • Life -threatening asthma.
• • Completed treatment for respiratory infection with antibiotics within 4 weeks of Screening.
• • History of acquired or inherited immunodeficiency disorders.
• • Oral immunotherapy, including stable maintenance dose allergen-specific oral immunotherapy.